Arteriovenous malformations (AVMs) of the brain are rare. The best population-level estimate puts prevalence at roughly 5.5 per 100,000 people, and the rate at which new symptomatic cases are detected is even lower, around 1 per 100,000 person-years. To put that in perspective, in a city of one million people, roughly 55 would be living with a brain AVM at any given time, and about 10 new cases would come to clinical attention each year.
Prevalence and Detection Rates
A widely cited population-based study published in the journal Stroke calculated the age- and sex-adjusted prevalence of brain AVMs at 5.47 per 100,000. More recent consensus recommendations from the American Heart Association use a slightly different metric, estimating prevalence at 1.3 per 100,000 person-years and the detection rate for symptomatic AVMs at 0.94 per 100,000 person-years. The gap between those numbers reflects a key reality: many AVMs exist silently and are never found during a person’s lifetime.
In a large, multiethnic study that tracked cases over a decade, about half of all identified brain AVMs (49%) were discovered only after they ruptured and caused bleeding. The other half (51%) were found unruptured, often during brain imaging ordered for headaches, seizures, or completely unrelated reasons. As MRI use has become more widespread, more AVMs are being caught before they bleed, which shifts the balance toward earlier, incidental discovery.
Who Gets Diagnosed
Brain AVMs are present from birth, forming during fetal development when blood vessels fail to create the normal network of tiny capillaries between arteries and veins. But they don’t usually cause problems right away. The average age at diagnosis is about 31 years, and most people learn they have one before age 40. That makes AVMs primarily a condition of young adults, which sets them apart from strokes caused by blood clots, which peak much later in life.
Men are diagnosed slightly more often than women. Across a study of nearly 1,300 patients from multiple countries, about 55% were male and 45% were female, a small but statistically significant difference. Whether this reflects a true biological difference in how often AVMs form or simply a difference in when and why people get brain imaging is still unclear.
The Hereditary Connection
For most people, a brain AVM is a one-off developmental accident with no known genetic cause. The exception is hereditary hemorrhagic telangiectasia (HHT), a genetic condition that causes abnormal blood vessels throughout the body. About 10.4% of people with HHT have a brain AVM, a rate roughly 2,000 times higher than the general population.
The risk varies by subtype. People with HHT Type 1 have a brain AVM prevalence of 13.4%, while those with HHT Type 2 have a much lower rate of 2.4%. If you have a family history of HHT, screening with brain MRI is standard practice because catching an AVM before it bleeds opens up more treatment options.
Risk of Bleeding
The question most people really want answered after learning how common AVMs are is how dangerous they are. For an AVM that has never ruptured, the annual risk of a first bleed is roughly 1% to 3%. That sounds low in any single year, but it compounds over a lifetime. A 30-year-old with an unruptured AVM faces decades of cumulative risk, which is why treatment decisions weigh the long-term math carefully.
Once an AVM has ruptured, the picture changes dramatically. The risk of a second bleed jumps to about five times higher than the initial risk, particularly within the first year after the hemorrhage. In one large registry of 1,555 patients, 12.9% experienced a second rupture during follow-up, translating to an annual re-rupture rate of 7.6%. That elevated risk is a major reason why ruptured AVMs are treated more aggressively.
What Happens After a Rupture
A ruptured brain AVM causes a type of hemorrhagic stroke. The severity depends on where the AVM is located, how much blood leaks, and how quickly the person receives care. Among people who experience a first AVM-related hemorrhage, the 30-day mortality rate is about 7%, and by six months it rises to roughly 12%. For context, people with unruptured AVMs who are simply being monitored have a six-month mortality rate of about 6%, reflecting the general risks of living with the condition.
Looking at the full picture, including people who die suddenly before reaching a hospital, the overall mortality rate for all AVM ruptures climbs to about 28%. A small but notable fraction of AVM-related sudden deaths (about 1.6% of symptomatic cases) are caused not by bleeding itself but by AVM-related seizures. Sudden prehospital death from hemorrhage specifically accounts for about 1.2% of first-ever ruptures.
These numbers illustrate why AVMs, despite being rare, are taken seriously. A condition that affects roughly 5 in 100,000 people carries a meaningful risk of life-altering or fatal bleeding, especially in younger adults who would otherwise be at very low risk for stroke.
How AVMs Compare to Other Conditions
To calibrate how rare AVMs truly are, it helps to compare them to other vascular brain conditions. Brain aneurysms, for instance, are present in roughly 2% to 3% of the general population, making them hundreds of times more common than AVMs. Stroke from all causes affects about 800 per 100,000 people over a lifetime. AVMs account for only about 1% to 2% of all strokes, but they account for a disproportionate share of strokes in people under 40.
The rarity of AVMs creates practical challenges. Many general practitioners will never see a case in their career, and even at major hospitals, individual surgeons may treat only a handful per year. This is why AVM care tends to be concentrated at specialized neurovascular centers, where teams have enough experience to weigh the risks of treatment against the risks of observation for each individual case.